Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of cancer treatment-induced bone loss.
Coleman RE, Rathbone E, Brown JE. Coleman RE, et al. Among authors: rathbone e. Nat Rev Rheumatol. 2013 Jun;9(6):365-74. doi: 10.1038/nrrheum.2013.36. Epub 2013 Mar 19. Nat Rev Rheumatol. 2013. PMID: 23507900 Review.
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R, Jyothirmayi R, Chakraborti P, Yuille F, Coleman RE. Rathbone EJ, et al. J Clin Oncol. 2013 Jul 20;31(21):2685-91. doi: 10.1200/JCO.2012.46.4792. Epub 2013 Jun 24. J Clin Oncol. 2013. PMID: 23796998 Clinical Trial.
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H; AZURE investigators. Coleman R, et al. Among authors: rathbone e. Lancet Oncol. 2014 Aug;15(9):997-1006. doi: 10.1016/S1470-2045(14)70302-X. Epub 2014 Jul 15. Lancet Oncol. 2014. PMID: 25035292 Clinical Trial.
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G, Maccon K, Bowman A, Hanby A, Bell R, Cameron D, Coleman R. Brown J, et al. Among authors: rathbone e. J Natl Cancer Inst. 2018 Aug 1;110(8):871-879. doi: 10.1093/jnci/djx280. J Natl Cancer Inst. 2018. PMID: 29425304 Free PMC article. Clinical Trial.
A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results.
Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J, Taylor C, Eastell R, Murden G, Brown SR, Rathbone E, Brown J. Winter M, et al. Among authors: rathbone e. J Bone Oncol. 2022 Jun 24;35:100442. doi: 10.1016/j.jbo.2022.100442. eCollection 2022 Aug. J Bone Oncol. 2022. PMID: 35800293 Free PMC article.
CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.
Coleman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I, Brown S. Coleman R, et al. Among authors: rathbone e. Trials. 2020 Jan 15;21(1):89. doi: 10.1186/s13063-019-3643-6. Trials. 2020. PMID: 31941523 Free PMC article. Clinical Trial.
54 results